Puma Biotechnology Earnings Estimate
| PBYI Stock | USD 6.94 0.15 2.21% |
Puma Biotechnology Revenue Breakdown by Earning Segment
By analyzing Puma Biotechnology's earnings estimates, investors can diagnose different trends across Puma Biotechnology's analyst sentiment over time as well as compare current estimates against different timeframes. As of now, Puma Biotechnology's Operating Profit Margin is decreasing as compared to previous years. The Puma Biotechnology's current Gross Profit Margin is estimated to increase to 0.87, while Gross Profit is projected to decrease to under 106.8 M. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Puma Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in producer price index.
Puma Biotechnology Earnings Estimation Breakdown
The calculation of Puma Biotechnology's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Puma Biotechnology is estimated to be 0.04 with the future projection ranging from a low of 0.04 to a high of 0.04. Please be aware that this consensus of annual earnings estimates for Puma Biotechnology is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
0.04 Lowest | Expected EPS | 0.04 Highest |
Puma Biotechnology Earnings Projection Consensus
Suppose the current estimates of Puma Biotechnology's value are higher than the current market price of the Puma Biotechnology stock. In this case, investors may conclude that Puma Biotechnology is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Puma Biotechnology's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2026 | Current EPS (TTM) | |
| 1 | 41.99% | 0.0 | 0.04 | 0.74 |
Puma Biotechnology Earnings per Share Projection vs Actual
Actual Earning per Share of Puma Biotechnology refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Puma Biotechnology predict the company's earnings will be in the future. The higher the earnings per share of Puma Biotechnology, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Puma Biotechnology Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Puma Biotechnology, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Puma Biotechnology should always be considered in relation to other companies to make a more educated investment decision.Puma Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Puma Biotechnology's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
null | null | null | null | null | 0 | ||
2025-11-06 | 2025-09-30 | 0.16 | 0.21 | 0.05 | 31 | ||
2025-08-07 | 2025-06-30 | 0.09 | 0.12 | 0.03 | 33 | ||
2025-04-30 | 2025-03-31 | -0.22 | 0.1 | 0.32 | 145 | ||
2025-02-26 | 2024-12-31 | 0.14 | 0.43 | 0.29 | 207 | ||
2024-11-07 | 2024-09-30 | 0.35 | 0.41 | 0.06 | 17 | ||
2024-08-01 | 2024-06-30 | -0.13 | -0.09 | 0.04 | 30 | ||
2024-05-02 | 2024-03-31 | -0.22 | -0.1 | 0.12 | 54 | ||
2024-02-29 | 2023-12-31 | 0.3 | 0.26 | -0.04 | 13 | ||
2023-11-02 | 2023-09-30 | 0.08 | 0.12 | 0.04 | 50 | ||
2023-08-03 | 2023-06-30 | 0.01 | 0.05 | 0.04 | 400 | ||
2023-05-04 | 2023-03-31 | -0.07 | 0.03 | 0.1 | 142 | ||
2023-03-02 | 2022-12-31 | 0.01 | -0.12 | -0.13 | 1300 | ||
2022-11-03 | 2022-09-30 | -0.05 | -0.01 | 0.04 | 80 | ||
2022-08-04 | 2022-06-30 | 0.0102 | 0.21 | 0.1998 | 1958 | ||
2022-05-05 | 2022-03-31 | -0.17 | -0.08 | 0.09 | 52 | ||
2022-03-03 | 2021-12-31 | -0.09 | 0.1 | 0.19 | 211 | ||
2021-11-04 | 2021-09-30 | -0.31 | -0.9 | -0.59 | 190 | ||
2021-08-05 | 2021-06-30 | -0.27 | -0.13 | 0.14 | 51 | ||
2021-05-06 | 2021-03-31 | 0.09 | 0.4 | 0.31 | 344 | ||
2021-02-25 | 2020-12-31 | -0.31 | -0.38 | -0.07 | 22 | ||
2020-11-05 | 2020-09-30 | -0.39 | -0.79 | -0.4 | 102 | ||
2020-08-06 | 2020-06-30 | -0.3 | 0.08 | 0.38 | 126 | ||
2020-05-07 | 2020-03-31 | -0.77 | -0.43 | 0.34 | 44 | ||
2020-02-20 | 2019-12-31 | -0.48 | -0.29 | 0.19 | 39 | ||
2019-11-06 | 2019-09-30 | -0.71 | -0.44 | 0.27 | 38 | ||
2019-08-08 | 2019-06-30 | -0.95 | -0.97 | -0.02 | 2 | ||
2019-05-09 | 2019-03-31 | -0.68 | -0.26 | 0.42 | 61 | ||
2019-02-28 | 2018-12-31 | -0.77 | -0.8 | -0.03 | 3 | ||
2018-11-01 | 2018-09-30 | -0.97 | -0.37 | 0.6 | 61 | ||
2018-08-09 | 2018-06-30 | -1.26 | -1.17 | 0.09 | 7 | ||
2018-05-09 | 2018-03-31 | -1 | -0.65 | 0.35 | 35 | ||
2018-03-01 | 2017-12-31 | -1.97 | -1.71 | 0.26 | 13 | ||
2017-11-09 | 2017-09-30 | -2.58 | -2.07 | 0.51 | 19 | ||
2017-08-09 | 2017-06-30 | -2.04 | -2.1 | -0.06 | 2 | ||
2017-05-10 | 2017-03-31 | -1.98 | -1.97 | 0.01 | 0 | ||
2017-03-01 | 2016-12-31 | -1.92 | -2.04 | -0.12 | 6 | ||
2016-11-09 | 2016-09-30 | -1.96 | -2.02 | -0.06 | 3 | ||
2016-08-09 | 2016-06-30 | -2.18 | -2.05 | 0.13 | 5 | ||
2016-05-10 | 2016-03-31 | -1.99 | -2.19 | -0.2 | 10 | ||
2016-02-29 | 2015-12-31 | -1.95 | -1.9 | 0.05 | 2 | ||
2015-11-09 | 2015-09-30 | -1.84 | -1.87 | -0.03 | 1 | ||
2015-08-10 | 2015-06-30 | -1.55 | -2.01 | -0.46 | 29 | ||
2015-05-11 | 2015-03-31 | -1.35 | -1.66 | -0.31 | 22 | ||
2015-03-02 | 2014-12-31 | -1.19 | -1.57 | -0.38 | 31 | ||
2014-11-10 | 2014-09-30 | -1.21 | -1.19 | 0.02 | 1 | ||
2014-08-11 | 2014-06-30 | -0.66 | -1.29 | -0.63 | 95 | ||
2014-05-12 | 2014-03-31 | -0.48 | -0.67 | -0.19 | 39 | ||
2014-03-03 | 2013-12-31 | -0.49 | -0.56 | -0.07 | 14 | ||
2013-11-12 | 2013-09-30 | -0.46 | -0.5 | -0.04 | 8 | ||
2013-08-06 | 2013-06-30 | -0.43 | -0.44 | -0.01 | 2 | ||
2013-05-09 | 2013-03-31 | -0.63 | -0.41 | 0.22 | 34 | ||
2013-03-31 | 2012-12-31 | -0.75 | -0.83 | -0.08 | 10 | ||
2012-11-14 | 2012-09-30 | -0.52 | -1.29 | -0.77 | 148 | ||
2012-08-14 | 2012-06-30 | -0.35 | -0.22 | 0.13 | 37 | ||
2012-05-15 | 2012-03-31 | -0.25 | -0.57 | -0.32 | 128 |
About Puma Biotechnology Earnings Estimate
The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Puma Biotechnology earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Puma Biotechnology estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Puma Biotechnology fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.| Last Reported | Projected for Next Year | ||
| Retained Earnings | -1.2 B | -1.1 B | |
| Retained Earnings Total Equity | -1.2 B | -1.3 B | |
| Earnings Yield | 0.18 | 0.19 | |
| Price Earnings Ratio | 4.41 | 4.19 | |
| Price Earnings To Growth Ratio | 0.16 | 0.17 |
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Puma Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in producer price index. For more detail on how to invest in Puma Stock please use our How to Invest in Puma Biotechnology guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is there potential for Biotechnology market expansion? Will Puma introduce new products? Factors like these will boost the valuation of Puma Biotechnology. Anticipated expansion of Puma directly elevates investor willingness to pay premium valuations. Understanding fair value requires weighing current performance against future potential. All the valuation information about Puma Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.58) | Earnings Share 0.74 | Revenue Per Share | Quarterly Revenue Growth (0.32) | Return On Assets |
The market value of Puma Biotechnology is measured differently than its book value, which is the value of Puma that is recorded on the company's balance sheet. Investors also form their own opinion of Puma Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Puma Biotechnology's true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Puma Biotechnology's market value can be influenced by many factors that don't directly affect Puma Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Puma Biotechnology's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Puma Biotechnology should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Puma Biotechnology's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.